Morgan Stanley Outlook Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Shares
13 transactions
Others Institutions Holding OTLK
# of Institutions
3Shares Held
31.5KCall Options Held
0Put Options Held
0About Outlook Therapeutics, Inc.
- Ticker OTLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 226,144,992
- Market Cap $317M
- Description
- Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...